February 2020

A team from the Biopharmaceutical Development Program is developing a new autologous cell therapy line that uses engineered chimeric antigen receptor T cells to treat acute myeloid leukemia, a particularly aggressive form of pediatric blood cancer. This foray into cell immunotherapy represents a new avenue of research and development for the BDP, which has traditionally focused on biologics to fight cancer, HIV, and rare diseases.

Resource management in the form of “outsourcing” continues to be a valuable tool for the Operations and Maintenance (O&M) department. The O&M department uses this resource as an integral part of its approach to customer service.